Dataset Information

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

ABSTRACT: Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

SUBMITTER: Page DB

PROVIDER: S-EPMC6783471 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

Page David B DB Bear Harry H Prabhakaran Sangeetha S Gatti-Mays Margaret E ME Thomas Alexandra A Cobain Erin E McArthur Heather H Balko Justin M JM Gameiro Sofia R SR Nanda Rita R Gulley James L JL Kalinsky Kevin K White Julia J Litton Jennifer J Chmura Steven J SJ Polley Mei-Yin MY Vincent Benjamin B Cescon David W DW Disis Mary L ML Sparano Joseph A JA Mittendorf Elizabeth A EA Adams Sylvia S

NPJ breast cancer 20191008

Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and pr ...[more]

PMID: 31602395

Dataset Information

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

Publications

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
| S-EPMC10132987 | biostudies-literature

Oncolytic virus and PD-1/PD-L1 blockade combination therapy.
| S-EPMC6074764 | biostudies-literature

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
| S-EPMC6209395 | biostudies-literature

Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.
| S-EPMC7453903 | biostudies-literature

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
| S-EPMC8780712 | biostudies-literature

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
| S-EPMC5290437 | biostudies-literature

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
| S-EPMC5889289 | biostudies-literature

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.
| S-EPMC9470119 | biostudies-literature

Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
| S-EPMC7539780 | biostudies-literature

Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
| S-EPMC10085570 | biostudies-literature